Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase NA 1

Status

Unknown 1Terminated 1Not yet recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3

Conditions

Carcinoma, Non-Small-Cell Lung 129Melanoma 90Squamous Cell Carcinoma of Head and Neck 88Breast Neoplasms 70Triple Negative Breast Neoplasms 64Parkinson Disease 4, Autosomal Dominant Lewy Body 45Head and Neck Neoplasms 45Lung Neoplasms 38Ovarian Neoplasms 37Neoplasms 37Neoplasm Metastasis 37Colorectal Neoplasms 37Stomach Neoplasms 36Carcinoma, Renal Cell 34Carcinoma, Transitional Cell 31Pancreatic Neoplasms 29Urinary Bladder Neoplasms 28Carcinoma, Hepatocellular 27Recurrence 21Hodgkin Disease 21Uterine Cervical Neoplasms 20Endometrial Neoplasms 20Prostatic Neoplasms 18Esophageal Neoplasms 18Sarcoma 17Glioblastoma 17Brain Neoplasms 16Fallopian Tube Neoplasms 15Esophageal Squamous Cell Carcinoma 15Carcinoma, Squamous Cell 14

Interventions

Pemetrexed 4pembrolizumab 3Ramucirumab 2Gemcitabine 2Carboplatin 2vistusertib 1vandetanib 1tusamitamab ravtansine 1telomerase reverse transcriptase p572Y, human 1sintilimab 1olaparib 1necitumumab 1icotinib 1durvalumab 1dacomitinib 1capivasertib 1Vinorelbine 1LY3023414 1Injections 1Immune Checkpoint Inhibitors 1Erlotinib Hydrochloride 1Drug Therapy 1Docetaxel 1Cisplatin 1Bevacizumab 1AZD4547 1AZD 8931 1AZD 6244 11-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Non-small Cell Lung Cancer Metastatic × pembrolizumab × Clear all
NCT04394624 2025-06-06

CARMEN-LC04

Sanofi

Phase 2 Terminated
31 enrolled 22 charts
Thoracic

Non-small Cell Lung Cancer Metastatic

NCT06045767 2024-06-03

T-Cell Repertoire Sequencing: Assessing Pembrolizumab Efficacy in Advanced Non-small Lung Cancer

Tel Aviv Medical Center

Phase 2 Not yet recruiting
30 enrolled
Thoracic

Non-small Cell Lung Cancer Metastatic

NCT03656094 2019-12-09

Chemotherapy With Pembrolizumab Continuation After Progression to PD-1/L1 Inhibitors

Samsung Medical Center

Phase 2 Unknown
98 enrolled
Thoracic

Non-small Cell Lung Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡